Overview

Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT

Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-center observational study to assess addition of Rituximab in the treatment of previously untreated patients with Diffuse Large B-Cell Lymphomas(DLBCL) over an enrollment period of 60 months. Patients in this study are enrolling for the collection of their data on observations made during normal clinical practice.
Details
Lead Sponsor:
Stanford University
Treatments:
Rituximab